Endocannabinoids are signaling molecules your body produces naturally that help regulate pain, appetite, mood, immune function, and more. They’re structurally similar to the active compounds in cannabis, which is how they got their name, but your body makes them on demand from fatty acids already present in cell membranes. The two most studied endocannabinoids are anandamide and 2-AG, and together with their receptors and the enzymes that break them down, they form what scientists call the endocannabinoid system (ECS).
The Two Main Endocannabinoids
Anandamide was the first endocannabinoid identified, isolated from pig brain tissue in 1992 by researchers Bill Devane and Raphael Mechoulam. Its scientific name is arachidonoyl ethanolamide, but Mechoulam named it after “ananda,” the Sanskrit word for bliss. Your body builds anandamide from arachidonic acid (a type of omega-6 fatty acid) and ethanolamine, both pulled from cell membrane components called phospholipids.
2-AG (2-arachidonoylglycerol) was discovered shortly after and is the second major endocannabinoid. It’s also derived from arachidonic acid-containing phospholipids but through a different breakdown pathway. The two molecules behave differently at receptors: 2-AG is a full activator with lower potency, while anandamide is a partial activator with higher potency. In practical terms, 2-AG produces a stronger but less precise signal, while anandamide is more targeted.
Unlike many signaling molecules, endocannabinoids aren’t stored in advance. Your cells manufacture them on the spot when needed, which keeps their effects tightly localized and brief.
How Endocannabinoids Signal Backward
Most chemical messengers in the brain travel in one direction: from a sending neuron to a receiving neuron. Endocannabinoids do the opposite. When a receiving neuron becomes highly active, it produces endocannabinoids that travel backward across the gap between nerve cells and land on the sending neuron. There, they bind to receptors and dial down the release of other chemical messengers.
This backward (retrograde) signaling acts like a volume knob. If a nerve circuit is firing too intensely, whether it’s transmitting pain signals, stress responses, or excitatory activity, endocannabinoids can temporarily turn it down. This suppression can be brief, lasting seconds to minutes, or it can trigger longer-lasting changes in how strongly two neurons communicate. Scientists consider endocannabinoids the best-characterized retrograde messengers in the brain, and this mechanism has been documented across many brain regions.
CB1 and CB2 Receptors
Endocannabinoids act on two primary receptor types, and their locations explain a lot about what the system does.
CB1 receptors are concentrated in the brain, where they influence mood, memory, pain perception, appetite, and coordination. They’re also present in smaller numbers in peripheral tissues. CB2 receptors, by contrast, are found mostly outside the brain: on circulating immune cells, in the spleen, on bone cells, and on specialized immune cells in the liver. Under normal conditions, CB2 expression in the brain is limited mainly to a few specific areas in the brainstem and hippocampus.
One notable feature of CB2 receptors is that their numbers surge in response to inflammation or injury. When tissue becomes inflamed, CB2 receptors multiply on immune cells in the affected area, including in the skin, where they appear on surface cells, immune cells, and certain white blood cells. This makes CB2 a key player in how the endocannabinoid system manages inflammatory responses.
How the Body Breaks Them Down
Because endocannabinoids are made on demand, they also need to be cleared quickly. Two enzymes handle this. FAAH (fatty acid amide hydrolase) breaks down anandamide. MAGL (monoacylglycerol lipase) breaks down 2-AG. This rapid production-and-destruction cycle is what keeps endocannabinoid signaling precise and localized, unlike a drug that circulates through the entire bloodstream for hours.
What the Endocannabinoid System Regulates
The ECS touches a surprisingly wide range of body functions, all tied to maintaining balance.
Pain. Both CB1 and CB2 receptors are involved in pain regulation. CB2 receptor activation has been shown to reduce pain perception in acute inflammatory conditions, while CB1 receptors modulate pain signals in the brain and spinal cord. The system’s role in pain control is one reason cannabis-based therapies have drawn so much clinical interest.
Appetite and energy balance. Endocannabinoids stimulate appetite by acting on CB1 receptors in brain regions that control food intake. They promote pathways that favor energy storage, which is why cannabis use famously increases hunger. The system also influences fat production and overall energy balance.
Immune function. CB2 receptors are closely linked to immune regulation and have anti-inflammatory effects. Blocking CB2 receptors can prevent inflammatory cells from migrating to a site of injury, while CB1 receptor activity in the liver influences inflammation and oxidative stress. The system essentially helps calibrate how aggressively your immune system responds.
How Endocannabinoids Compare to THC
THC, the psychoactive compound in cannabis, mimics endocannabinoids by binding to the same receptors. But there are critical differences. Anandamide and 2-AG are produced in tiny amounts, exactly where needed, and broken down within seconds to minutes. THC, especially when ingested orally, has a half-life of 20 to 60 hours, meaning it lingers in the body far longer.
The other major difference is scope. Endocannabinoids activate CB1 receptors only at specific synapses where they’re released. THC floods the entire brain, activating CB1 receptors everywhere at once. THC most closely mimics anandamide’s activity, since both are partial activators at CB1 receptors, but THC also interferes with 2-AG signaling by competing for the same binding sites. This widespread, prolonged activation is what produces the “high” and the side effects that endocannabinoids themselves don’t cause.
Endocannabinoid Deficiency
Some researchers have proposed that certain hard-to-treat conditions may stem from an underactive endocannabinoid system. The strongest evidence for this “clinical endocannabinoid deficiency” theory involves three conditions: migraine, fibromyalgia, and irritable bowel syndrome. These disorders share notable features, including heightened pain sensitivity and central sensitization, where the nervous system amplifies pain signals beyond what the stimulus warrants.
Studies have found that reduced endocannabinoid activity in the spinal cord is associated with increased pain sensitivity, and that restoring endocannabinoid levels can reduce it. All three conditions have historically been difficult to treat with standard medications and have often been dismissed as psychosomatic, which makes the prospect of an identifiable biological mechanism particularly significant for patients.
Lifestyle Factors That Boost Endocannabinoid Levels
Exercise is the most well-supported way to naturally increase endocannabinoid production. High-intensity physical activity triggers the release of both anandamide and 2-AG, which then produce short-term pain-relieving effects. This is part of what’s behind the “runner’s high,” a phenomenon long attributed to endorphins alone. More recent research points to endocannabinoids as the primary driver of that post-exercise euphoria and pain reduction, with endorphins playing a supporting role.
The effect is temporary: endocannabinoids generated during exercise act as short-term circuit breakers, dampening pain and stress for a variable window after activity. But regular exercise appears to keep the system responsive and well-tuned, making it one of the most accessible ways to support endocannabinoid function.